Are we ready for long‐acting? A feasibility evaluation of long‐acting cabotegravir–rilpivirine in clinical practice-Reference-Cited by-同舟云学术

Are we ready for long‐acting? A feasibility evaluation of long‐acting cabotegravir–rilpivirine in clinical practice

Published:2022-06-09 Issue:10 Volume:94 Page:4970-4974
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:Journal of Medical Virology

Author:

Borghetti Alberto¹,Farinacci Damiano¹^ORCID,Ciccullo Arturo²^ORCID,Dusina Alex¹,Moschese Davide³,Iannone Valentina⁴,D'Angelillo Anna⁴,Lombardi Francesca⁴,Donne Valentina Delle⁴,Massaroni Valentina⁴,Visconti Elena¹,Tamburrini Enrica¹⁴,Di Giambenedetto Simona¹⁴

Affiliation:

1. Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Malattie Infettive Roma Italy

2. UOC Malattie Infettive, Ospedale S. Salvatore, L'Aquila Coppito Italy

3. Dipartimento di Malattie Infettive I Divisione di Malattie Infettive ASST Fatebenefratelli‐Sacco Milano Italy

4. Dipartimento di Sicurezza e Bioetica Sezione Malattie Infettive Università Cattolica del Sacro Cuore Roma Italy

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.27890

Reference15 articles.

1. Effectiveness of antiretroviral therapy in the single-tablet regimen era

2. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

3. Panel on Antiretrovirals Guidelines for Adults and Adolescents. 2021. Guideline for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Accessed May 4 2021. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf

4. Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study

5. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Low Uptake of Long-Acting Injectables in the First 2.5 Years Following Approval Among a Cohort of People Living With HIV;Open Forum Infectious Diseases;2024-04-26

2. Acceptability of Switching to Long-Acting Cabotegravir and Rilpivirine Among People Living with HIV on Dolutegravir/Rilpivirine Combination: A Single-Center Experience;AIDS Research and Human Retroviruses;2023-10-23

3. The propensity for long‐acting cabotegravir and rilpivirine every 2 months among HIV‐infected people eligible for treatment;Journal of Medical Virology;2022-11-30